NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Forecast & News

Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALXN shares have increased by 0.3% and is now trading at $84.01. View which stocks have been mosted impacted by Coronavirus.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alexion Pharmaceuticals.

Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for Alexion Pharmaceuticals.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its quarterly earnings results on Thursday, January, 30th. The biopharmaceutical company reported $2.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.60 by $0.11. The biopharmaceutical company had revenue of $1.38 billion for the quarter, compared to the consensus estimate of $1.32 billion. Alexion Pharmaceuticals had a return on equity of 21.29% and a net margin of 48.17%. The company's revenue was up 22.7% compared to the same quarter last year. During the same period last year, the firm earned $2.14 EPS. View Alexion Pharmaceuticals' earnings history.

Alexion Pharmaceuticals issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share (EPS) guidance of $10.65-$10.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.96. The company issued revenue guidance of $5.50-$5.56 billion, compared to the consensus revenue estimate of $5.51 billion.

21 Wall Street analysts have issued twelve-month target prices for Alexion Pharmaceuticals' stock. Their forecasts range from $110.00 to $180.00. On average, they expect Alexion Pharmaceuticals' share price to reach $148.20 in the next twelve months. This suggests a possible upside of 76.4% from the stock's current price. View analysts' price targets for Alexion Pharmaceuticals.

Press coverage about ALXN stock has trended very negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alexion Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutAlexion Pharmaceuticals.

Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Gilead Sciences (GILD), Celgene (CELG), Netflix (NFLX), AbbVie (ABBV), Visa (V), Broadcom (AVGO) and Biogen (BIIB).

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wealth Quarterback LLC (6.93%), FMR LLC (6.64%), State Street Corp (4.95%), Renaissance Technologies LLC (1.69%), Artisan Partners Limited Partnership (1.49%) and Geode Capital Management LLC (1.44%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Indrani Lall Franchini, John J Orloff, Ludwig Hantson and Paul J Clancy. View institutional ownership trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artisan Partners Limited Partnership, Franklin Resources Inc., Franklin Resources Inc., Partner Fund Management L.P., FIL Ltd, Sei Investments Co., and Jennison Associates LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Aradhana Sarin, Bros Advisors Lp Baker, and Indrani Lall Franchini. View insider buying and selling activity for Alexion Pharmaceuticals.

ALXN stock was bought by a variety of institutional investors in the last quarter, including Wealth Quarterback LLC, Norges Bank, AQR Capital Management LLC, Renaissance Technologies LLC, Bank of Montreal Can, LSV Asset Management, Thrivent Financial for Lutherans, and Man Group plc. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, and Christopher J Coughlin. View insider buying and selling activity for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $84.01.

Alexion Pharmaceuticals has a market capitalization of $18.60 billion and generates $4.99 billion in revenue each year. The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis. Alexion Pharmaceuticals employs 3,082 workers across the globe. View additional information about Alexion Pharmaceuticals.

The official website for Alexion Pharmaceuticals is http://www.alexion.com/.

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]